SLGC NASDAQ

SomaLogic, Inc. is a U.S.-based enterprise specializing in the identification of protein biomarkers and the development of clinical diagnostic solutions. A core aspect of its technology involves the creation of slow off-rate modified aptamers (SOMAmers) – unique nucleic acid-based reagents meticulously designed to specifically bind with their target proteins. The company also provides its proprietary SomaScan services, which enable the simultaneous detection and precise quantification of numerous proteins within intricate biological samples. This integrated SOMAmer and SomaScan platform empowers researchers to analyze diverse biological specimens, uncovering protein biomarker signatures invaluable for pharmaceutical discovery and development initiatives. Furthermore, the biomarker insights gleaned from SomaScan are instrumental in developing diagnostic applications across a range of conditions, such as cardiovascular and metabolic diseases, nonalcoholic steatohepatitis (NASH), and for general wellness monitoring. SomaLogic additionally furnishes SomaSignal tests, available for both research use only (RUO) and as laboratory-developed tests (LDTs). The firm caters to both research and clinical clients, primarily comprising pharmaceutical and biotechnology companies, as well as academic research institutions. These offerings support various stages of drug development, facilitate the analysis of clinical trials, and contribute to novel insights into human biology through the investigation of protein-protein and protein-gene interactions. Established in 1999, SomaLogic maintains its corporate headquarters in Boulder, Colorado.